Abstract: The present application relates to compounds comprising an ester, a thioester, or a hydrazide moiety and methods of synthesizing these compounds. The present application also relates to pharmaceutical compositions containing the compounds and methods of treating cell proliferative disorders mediated by the Hedgehog (Hh) signaling pathway, such as cancer, by administering the compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: The present application relates to compounds comprising an ester, a thioester, or a hydrazide moiety and methods of synthesizing these compounds. The present application also relates to pharmaceutical compositions containing the compounds and methods of treating cell proliferative disorders mediated by the Hedgehog (Hh) signaling pathway, such as cancer, by administering the compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: Embodiments herein relate to compositions and methods for stabilizing Flaviviruses. In certain embodiments, compositions and methods disclosed herein concern stabilizing live, attenuated or unattenuated (e.g. live whole) flaviviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated or unattenuated flaviviruses. Other embodiments relate to improved formulations for prolonging stabilization of live attenuated or unattenuated Flaviviruses during manufacturing, storage, accelerated storage and transport. Yet other embodiments relate to uses of compositions disclosed herein in kits for transportable applications and methods.

Abstract: Embodiments herein relate to compositions and methods for stabilizing Flaviviruses. In certain embodiments, compositions and methods disclosed herein concern stabilizing live, attenuated or unattenuated (e.g. live whole) flaviviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated or unattenuated flaviviruses. Other embodiments relate to improved formulations for prolonging stabilization of live attenuated or unattenuated Flaviviruses during manufacturing, storage, accelerated storage and transport. Yet other embodiments relate to uses of compositions disclosed herein in kits for transportable applications and methods.

Abstract: Provided herein are compounds, pharmaceutical compositions, and methods for inhibiting the ENL YEATS domain. Further, provided herein are compounds, pharmaceutical compositions, and methods for the treatment of leukemia.

Abstract: The present application relates to compounds comprising an ester, a thioester, or a hydrazide moiety and methods of synthesizing these compounds. The present application also relates to pharmaceutical compositions containing the compounds and methods of treating cell proliferative disorders mediated by the Hedgehog (Hh) signaling pathway, such as cancer, by administering the compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: Embodiments herein relate to compositions and methods for stabilizing Flaviviruses. In certain embodiments, compositions and methods disclosed herein concern stabilizing live, attenuated or unattenuated (e.g. live whole) flaviviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated or unattenuated flaviviruses. Other embodiments relate to improved formulations for prolonging stabilization of live attenuated or unattenuated Flaviviruses during manufacturing, storage, accelerated storage and transport. Yet other embodiments relate to uses of compositions disclosed herein in kits for transportable applications and methods.

Abstract: The present application relates to compounds comprising an ester, a thioester, or a hydrazide moiety and methods of synthesizing these compounds. The present application also relates to pharmaceutical compositions containing the compounds and methods of treating cell proliferative disorders mediated by the Hh signaling pathway, such as cancer, by administering the compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: Embodiments herein relate to compositions and methods for stabilizing Flaviviruses. In certain embodiments, compositions and methods disclosed herein concern stabilizing live, attenuated or unattenuated (e.g. live whole) flaviviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated or unattenuated flaviviruses. Other embodiments relate to improved formulations for prolonging stabilization of live attenuated or unattenuated Flaviviruses during manufacturing, storage, accelerated storage and transport. Yet other embodiments relate to uses of compositions disclosed herein in kits for transportable applications and methods.

Abstract: The present application relates to compounds comprising an ester, a thioester, or a hydrazide moiety and methods of synthesizing these compounds. The present application also relates to pharmaceutical compositions containing the compounds and methods of treating cell proliferative disorders mediated by the Hh signaling pathway, such as cancer, by administering the compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: The present application relates to compounds comprising an ester, a thioester, or a hydrazide moiety and methods of synthesizing these compounds. The present application also relates to pharmaceutical compositions containing the compounds and methods of treating cell proliferative disorders mediated by the Hh signaling pathway, such as cancer, by administering the compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: Embodiments herein relate to compositions and methods for stabilizing Flaviviruses. In certain embodiments, compositions and methods disclosed herein concern stabilizing live, attenuated or unattenuated (e.g. live whole) flaviviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated or unattenuated flaviviruses. Other embodiments relate to improved formulations for prolonging stabilization of live attenuated or unattenuated Flaviviruses during manufacturing, storage, accelerated storage and transport. Yet other embodiments relate to uses of compositions disclosed herein in kits for transportable applications and methods.

Abstract: The present application relates to compounds comprising an ester, a thioester, or a hydrazide moiety and methods of synthesizing these compounds. The present application also relates to pharmaceutical compositions containing the compounds and methods of treating cell proliferative disorders mediated by the Hh signaling pathway, such as cancer, by administering the compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: The invention is directed to ammonium paratungstate decahydrate containing at least 75% of crystals having a length of at least 200 ?m and having a ratio of length to width of less than 4.5:1.

Abstract: A method for preparing ammonium heptamolybdate with the steps of: i) adding a molybdenum-containing organic phase to a liquid-liquid reextraction apparatus or to a desorption apparatus, and ii) directly cold-crystallization ammonium heptamolybdate by cooling the resulting reextraction or desorption solution.

Abstract: The invention is directed to ammonium paratungstate decahydrate containing at least 75% of crystals having a length of at least 200 ?m and having a ratio of length to width of less than 4.5:1.

Abstract: The invention is directed to a method for the production of ammonium paratungstate tetrahydrate by thermal treatment of ammonium paratungstate decahydrate in an aqueous suspension. The ammonium paratungstate tetrahydrate can be produced with high purity and high yield. The production method may furthermore be carried out in a simple and energy-efficient manner.

Abstract: The invention is directed to a process for the continuous preparation of ammonium paratungstate hydrate by back reextraction of a tungsten-laden organic phase with an ammonia-containing aqueous solution in a mixer-settler apparatus. The reextraction is carried out at an NH3:W molar ratio of from 0.83 to 1.30, and a volume feed ratio of the tungsten-laden organic phase to the ammonia-containing aqueous solution of from 5 to 25. The above crystalline is in high purity and in high yield. The production method can be carried out in a simple and energy-efficient manner.

Abstract: The invention is directed to a method for the production of ammonium paratungstate tetrahydrate by thermal treatment of ammonium paratungstate decahydrate in an aqueous suspension. The ammonium paratungstate tetrahydrate can be produced with high purity and high yield. The production method may furthermore be carried out in a simple and energy-efficient manner.

Abstract: The invention is directed to a method for the production of ammonium paratungstate tetrahydrate by thermal treatment of ammonium paratungstate decahydrate in an aqueous suspension. The ammonium paratungstate tetrahydrate can be produced with high purity and high yield. The production method may furthermore be carried out in a simple and energy-efficient manner.